CDK4 and essential thrombocythemia: In the advanced breast cancer (ABC) setting, the combination of ET with cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitors can combat endocrine resistance mechanisms associated with ET, and, as such, represents a contemporary therapeutic breakthrough.10